Corcept Therapeutics (CORT) Total Non-Current Liabilities (2017 - 2026)

Corcept Therapeutics has reported Total Non-Current Liabilities for 10 years, with the latest figure at $167.4 million in Q2 2026.

• Quarterly Total Non-Current Liabilities rose 11.44% year-over-year to $167.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $167.4 million (up 11.44% YoY) and the FY2025 annual result came in at $173.7 million, up 18.24% from the prior year.
• Total Non-Current Liabilities rose to $167.4 million in Q2 2026 per CORT's latest filing, from $161.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $177.6 million in Q3 2025 and troughed at $49.1 million in Q2 2022.
• A 5-year average of $116.3 million and a median of $114.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities advanced 8.05% in 2022, then soared 129.65% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $72.5 million in 2022, then surged by 44.16% to $104.5 million in 2023, then soared by 40.55% to $146.9 million in 2024, then rose by 18.24% to $173.7 million in 2025, then declined by 3.59% to $167.4 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $167.4 million, $161.6 million, and $173.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.